308690
Geographic Disparities in Treatment of Recurrent Respiratory Papillomatosis (RRP): A Clinical Chart Review of Pediatric Cases in Panama from 2003-2013
Methods: Clinical chart review of RRP cases seen at the only 2 pediatric referral centers in Panama from 2003-2013. Variables of interest included place of residence, time between first symptom and diagnosis, and number of documented surgeries.
Results: A total of 20 cases were reviewed. Average time between first symptom and diagnosis was 2.0 years (n=8, SD=1.7) and 1.0 years (n=5, SD=.9) among patients living in the province of Panama versus distant provinces, respectively. Patients living in the province of Panama were 12.5 times more likely to have undergone at least 5 surgeries when compared to patients living in distant provinces (CI 1.1-143.4; p<0.05).
Discussion: Among our sample, there did not appear to be a delay in diagnosis when comparing patients based on their province of origin. When patients living in and around the capital city versus distant provinces were compared, urban patients were more likely to have undergone >5 surgical procedures, suggesting that treatment patterns are geographically dependent. More research is necessary to determine whether this demonstrates decreased access to and utilization of surgical services based on geography, or if cases in urban communities are more severe, requiring more aggressive treatment.
Learning Areas:
Chronic disease management and preventionEpidemiology
Learning Objectives:
Describe the course of treatment of cases of pediatric recurrent respiratory papilllomatosis seen at two large urban pediatric hospitals in Panama.
Keyword(s): Pediatrics, International Health
Qualified on the content I am responsible for because: I have been conducting otolaryngological research for the past year and a half as a medical student and have the support of multiple clinical and basic science investigators.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.